Autopsy report · NCT05337735
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
Cause of deathOther
“PI Request”
Life of this trial
- Registered 4 months before it started.
- Suspended: paused, and may or may not restart.
- 140 participants planned (an estimate, not an actual count).
Vital statistics
- Status
- Suspended
- Phase
- Phase 2
- Sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Conditions
- Microsatellite High Cancers; Peritoneal Mesothelioma; Extrapulmonary High Grade; Neuroendocrine Carcinomas; Cervical Carcinoma; Hodgkin's Lymphoma
- Interventions
- XmAb20717
- Participants
- 140 (planned, not actual)
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.